Biomira modifies its aspirations

Presented with the opportunity to tie up with Chiron Corp.'s oncology business, Biomira Inc. chose to put on hold its own long-range plans for marketing a comprehensive cancer management package.

The companies last week announced a deal that will position BIOMF's Theratope cancer vaccine to be sold in the U.S. and Europe with CHIR's ProLeukin and Aredia cancer therapies, drugs that made up the bulk of CHIR's $183 million therapeutics business in 1996.

BIOMF (Edmonton, Alberta) has approached cancer management by developing

Read the full 805 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE